Featured Research

from universities, journals, and other organizations

Genetically-modified mice reveal another mechanism contributing to heart failure

Date:
February 3, 2010
Source:
University of Western Ontario
Summary:
Scientists have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure. The study shows how the decreased release of the neurotransmitter acetylcholine, a chemical messenger which slows cardiac activity, contributes to heart failure.

Scientists at the Robarts Research Institute at The University of Western Ontario, working in collaboration with researchers in Brazil, have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure.

The study, led by Marco Prado, Robert Gros and Vania Prado of London, Canada and Silvia Guatimosim of Brazil, shows how the decreased release of the neurotransmitter acetylcholine, a chemical messenger which slows cardiac activity, contributes to heart failure.

Heart failure affects close to a half million Canadians, often as a result of conditions including coronary disease, high blood pressure, diabetes and high alcohol or drug consumption. Cardiac output is controlled using two opposing divisions of the autonomic nervous system: the sympathetic nervous system which boosts the heart rate and the parasympathetic system which slows it by releasing acetylcholine.

"Lots of people have studied the system that increases the heart rate and that has been the hallmark; we know there's an increase in the sympathetic nervous system in people who have heart failure," explains Gros, a cardiovascular researcher and assistant professor in the Departments of Physiology & Pharmacology and Medicine at Western's Schulich School of Medicine & Dentistry.

"What we're now showing with this mouse model is that even if you have a functional sympathetic nervous system, if the other system, the parasympathetic system is dysfunctional or works less optimally than normal, you still end up with a sick heart. This opens up a whole new avenue that people have missed in the past."

Marco and Vania Prado genetically modified a line of mice with decreased secretion of acetylcholine originally for use in studying neuronal function in diseases such as Alzheimer's. But they found these mice, over time, developed changes in their hearts that progressively decreased their ability to pump blood, similar to what occurs with heart failure in humans.

"There are other mouse and rat models of heart failure, but what we haven't had before is a model where we specifically target this chemical messenger, acetylcholine," says Marco Prado, a professor in the Departments of Physiology & Pharmacology and Anatomy & Cell Biology. "One striking finding in this study is that heart dysfunction in these mice could be corrected by treating the animals with an existing drug which increases acetylcholine levels. Although it requires further study, this could provide a novel opportunity for treating failing hearts." The drug, Pyridostigmine, is currently approved for use in treating certain cases of muscle weakness.

In Canada, the study was supported by the Heart and Stroke Foundation and the Canadian Institutes of Health Research.


Story Source:

The above story is based on materials provided by University of Western Ontario. Note: Materials may be edited for content and length.


Journal Reference:

  1. Aline Lara, Denis D. Damasceno, Rita Pires, Robert Gros, Enιas R. Gomes, Mariana Gavioli, Ricardo F. Lima, Diogo Guimarγes, Patricia Lima, Carlos Roberto Bueno Jr, Anilton Vasconcelos, Danilo Roman-Campos, Cristiane A.S. Menezes, Raquel A. Sirvente, Vera M. Salemi, Charles Mady, Marc G. Caron, Anderson J. Ferreira, Patricia C. Brum, Rodrigo R. Resende, Jader S. Cruz, Marcus Vinicius Gomez, Vania F. Prado, Alvair P. De Almeida, Marco A.M. Prado, and Silvia Guatimosim. Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol. Cell. Biol, DOI: 10.1128/MCB.00996-09

Cite This Page:

University of Western Ontario. "Genetically-modified mice reveal another mechanism contributing to heart failure." ScienceDaily. ScienceDaily, 3 February 2010. <www.sciencedaily.com/releases/2010/02/100201145520.htm>.
University of Western Ontario. (2010, February 3). Genetically-modified mice reveal another mechanism contributing to heart failure. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/02/100201145520.htm
University of Western Ontario. "Genetically-modified mice reveal another mechanism contributing to heart failure." ScienceDaily. www.sciencedaily.com/releases/2010/02/100201145520.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins